NASDAQ
ELOX
Last Price
US $11.65
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Eloxx Pharmaceuticals, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio development.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
Eloxx Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Interest expense is not separately reported in Eloxx Pharmaceuticals, Inc.'s latest filing, so interest coverage cannot be calculated.
Financial risk - Profit margin growth.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Decreasing performance - ROA.
Eloxx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Eloxx Pharmaceuticals, Inc.'s return on equity of 72.03%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Eloxx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Eloxx Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Eloxx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Eloxx Pharmaceuticals, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Decreasing performance - Healthy earnings growth.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Decreasing performance - Healthy revenue growth.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Increasing performance - ROIC.
ROIC 66.15% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Eloxx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Decreasing performance - Revenue consistency.
Eloxx Pharmaceuticals, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Eloxx Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Eloxx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Eloxx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Eloxx Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Eloxx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
72.03%
Return on equity
ROIC: 66.15%
Valuation History
-2.1X
Price to Earnings
EV/EBITDA: -17.1X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $11.65
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.